James Fingleton1, Justin Travers2, Mathew Williams3, Thomas Charles3, Darren Bowles4, Rianne Strik3, Philippa Shirtcliffe4, Mark Weatherall5, Richard Beasley6. 1. Medical Research Institute of New Zealand, Wellington, New Zealand; Capital & Coast District Health Board, Wellington, New Zealand; Victoria University of Wellington, Wellington, New Zealand. 2. Medical Research Institute of New Zealand, Wellington, New Zealand; Hutt Valley District Health Board, Lower Hutt, New Zealand. 3. Medical Research Institute of New Zealand, Wellington, New Zealand. 4. Medical Research Institute of New Zealand, Wellington, New Zealand; Capital & Coast District Health Board, Wellington, New Zealand. 5. Capital & Coast District Health Board, Wellington, New Zealand; University of Otago Wellington, Wellington, New Zealand. 6. Medical Research Institute of New Zealand, Wellington, New Zealand; Capital & Coast District Health Board, Wellington, New Zealand; Victoria University of Wellington, Wellington, New Zealand. Electronic address: richard.beasley@mrinz.ac.nz.
Abstract
BACKGROUND: Asthma and chronic obstructive pulmonary disease (COPD) are heterogeneous disorders encompassing different phenotypes of airflow obstruction, which might differ in their response to treatment. OBJECTIVE: The aim of this study was to determine distinct phenotypes comprising the syndromes of asthma and COPD and the treatment responsiveness of these phenotypes to inhaled β-agonist, antimuscarinic, and corticosteroid therapy. METHODS: We undertook a cross-sectional study with 3 phases. In phase 1, 1,264 participants aged 18 to 75 years with self-reported current wheeze and breathlessness were identified from a random population sample of 16,459. In phase 2, 451 participants attended for detailed assessment, including responsiveness to inhaled salbutamol and ipratropium bromide. In phase 3, 168 steroid-naive participants were enrolled in a 12-week trial of inhaled budesonide. Cluster analysis was performed in 389 participants who completed phase 2 with full data. Treatment responsiveness was compared between phenotypes. RESULTS: Cluster analysis identified 5 phenotypes: moderate-to-severe childhood-onset atopic asthma, asthma-COPD overlap, obese-comorbid, mild childhood-onset atopic asthma, and mild intermittent. Bronchodilation after salbutamol was equal to or greater than that after ipratropium for all phenotypes. The moderate-to-severe childhood-onset atopic asthma, asthma-COPD overlap, and obese-comorbid phenotypes had greater efficacy with inhaled corticosteroid treatment than the mild intermittent group. CONCLUSION: Cluster analysis of adults with symptomatic airflow obstruction identifies 5 disease phenotypes, including asthma-COPD overlap and obese-comorbid phenotypes, and provides evidence that patients with the asthma-COPD overlap syndrome might benefit from inhaled corticosteroid therapy.
BACKGROUND:Asthma and chronic obstructive pulmonary disease (COPD) are heterogeneous disorders encompassing different phenotypes of airflow obstruction, which might differ in their response to treatment. OBJECTIVE: The aim of this study was to determine distinct phenotypes comprising the syndromes of asthma and COPD and the treatment responsiveness of these phenotypes to inhaled β-agonist, antimuscarinic, and corticosteroid therapy. METHODS: We undertook a cross-sectional study with 3 phases. In phase 1, 1,264 participants aged 18 to 75 years with self-reported current wheeze and breathlessness were identified from a random population sample of 16,459. In phase 2, 451 participants attended for detailed assessment, including responsiveness to inhaled salbutamol and ipratropium bromide. In phase 3, 168 steroid-naive participants were enrolled in a 12-week trial of inhaled budesonide. Cluster analysis was performed in 389 participants who completed phase 2 with full data. Treatment responsiveness was compared between phenotypes. RESULTS: Cluster analysis identified 5 phenotypes: moderate-to-severe childhood-onset atopic asthma, asthma-COPD overlap, obese-comorbid, mild childhood-onset atopic asthma, and mild intermittent. Bronchodilation after salbutamol was equal to or greater than that after ipratropium for all phenotypes. The moderate-to-severe childhood-onset atopic asthma, asthma-COPD overlap, and obese-comorbid phenotypes had greater efficacy with inhaled corticosteroid treatment than the mild intermittent group. CONCLUSION: Cluster analysis of adults with symptomatic airflow obstruction identifies 5 disease phenotypes, including asthma-COPD overlap and obese-comorbid phenotypes, and provides evidence that patients with the asthma-COPD overlap syndrome might benefit from inhaled corticosteroid therapy.
Authors: Prescott G Woodruff; Maarten van den Berge; Richard C Boucher; Christopher Brightling; Esteban G Burchard; Stephanie A Christenson; MeiLan K Han; Michael J Holtzman; Monica Kraft; David A Lynch; Fernando D Martinez; Helen K Reddel; Don D Sin; George R Washko; Sally E Wenzel; Antonello Punturieri; Michelle M Freemer; Robert A Wise Journal: Am J Respir Crit Care Med Date: 2017-08-01 Impact factor: 21.405
Authors: Anne G Wheaton; Roy A Pleasants; Janet B Croft; Jill A Ohar; Khosrow Heidari; David M Mannino; Yong Liu; Charlie Strange Journal: J Asthma Date: 2016-04-06 Impact factor: 2.515
Authors: Marc Miravitlles; Bernardino Alcázar; Francisco Javier Alvarez; Teresa Bazús; Myriam Calle; Ciro Casanova; Carolina Cisneros; Juan P de-Torres; Luis M Entrenas; Cristóbal Esteban; Patricia García-Sidro; Borja G Cosio; Arturo Huerta; Milagros Iriberri; José Luis Izquierdo; Antolín López-Viña; José Luis López-Campos; Eva Martínez-Moragón; Luis Pérez de Llano; Miguel Perpiñá; José Antonio Ros; José Serrano; Juan José Soler-Cataluña; Alfons Torrego; Isabel Urrutia; Vicente Plaza Journal: Int J Chron Obstruct Pulmon Dis Date: 2015-07-15
Authors: James Fingleton; Irene Braithwaite; Justin Travers; Darren Bowles; Rianne Strik; Rob Siebers; Cecile Holweg; John Matthews; Mark Weatherall; Richard Beasley Journal: Eur Respir J Date: 2016-02-25 Impact factor: 16.671
Authors: Timothy S C Hinks; Tom Brown; Laurie C K Lau; Hitasha Rupani; Clair Barber; Scott Elliott; Jon A Ward; Junya Ono; Shoichiro Ohta; Kenji Izuhara; Ratko Djukanović; Ramesh J Kurukulaaratchy; Anoop Chauhan; Peter H Howarth Journal: J Allergy Clin Immunol Date: 2016-02-03 Impact factor: 10.793
Authors: Giorgio Walter Canonica; Gianenrico Senna; Patrick D Mitchell; Paul M O'Byrne; Giovanni Passalacqua; Gilda Varricchi Journal: World Allergy Organ J Date: 2016-11-28 Impact factor: 4.084